Effect of Docosahexaenoic Acid on ROP in premature newborn

Effect of Docosahexaenoic Acid on prevention of retinopathy of prematurity in premature newborn

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20211226053528N1

Enrollment

124

Registered

2022-01-31

Start date

2021-03-21

Completion date

Unknown

Last updated

2022-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Retinopathy of prematurity. Retinopathy of prematurity

Interventions

Intervention 1: Intervention group: Infants took the DHA supplement (Kelvin kids Drop, manufactured by Zist Takhmir Company, Iran) orally (gavage or PO), 1 cc (40 mg) daily for 1 month. Intervention 2

Eligibility

Sex/Gender

All

Age

1 Days to 14 Days

Inclusion criteria

Inclusion criteria: Obtaining parental consent to participate in the study Premature newborn weighing less than1500 gr

Exclusion criteria

Exclusion criteria: Infants with asphyxia (umbilical cord pH less than 7 and BE less than -16) IUGR infants Definitive sepsis (positive blood culture), Newborns with severe congenital chromosomal abnormalities Newborns with congenital heart disease Infants with metabolic diseases Newborns with hypotension need vasodilators

Design outcomes

Primary

Measure	Time frame
Retinopathy stage (based on disease severity). Timepoint: before intervention and 1month after intervention. Method of measurement: Based on the severity of the disease (1-5 stages) by an ophthalmologist.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFateme Jafarnazari

Iran University of Medical Sciences

khosravi.n@iums.ac.ir+98 21 2304 6253

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026